TherapeuticsMD, Inc.
TXMD Healthcare Drug Manufacturers Specialty & Generic
TherapeuticsMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 71.6% from fiscal 2024. In the quarter to June 2026, revenue fell 8.72%, EPS fell 80.0% and free cash flow grew 104.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TXMD
TherapeuticsMD, Inc. (TXMD) Altman Z-score
TherapeuticsMD, Inc.'s Altman Z-score for fiscal 2025 is −34.36, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −34.36 | (0.30) |
| FY2024 | −34.06 | (3.88) |
| FY2023 | −30.18 | (17.11) |
| FY2022 | −13.06 | (2.22) |
| FY2021 | −10.84 | (2.70) |
| FY2020 | −8.13 | (4.88) |
| FY2019 | −3.26 | (3.19) |
| FY2018 | −0.06 | (51.58) |
| FY2017 | 51.52 | 10.16 |
| FY2016 | 41.36 | (52.93) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.26 | — | 0.31 | |
| Retained earnings / total assets | (25.29) | — | −35.41 | |
| EBIT / total assets | (0.12) | — | −0.38 | |
| Market value of equity / total liabilities | 1.75 | — | 1.05 | |
| Sales / total assets | 0.08 | — | 0.08 | |
| Altman Z-score | Distress zone | −34.36 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −78.93 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| UPC Universe Pharmaceuticals INC compare | 0.6× |
| CPHI China Pharma Holdings, Inc. compare | −2.2× |
| AYTU Aytu BioPharma, Inc. compare | −4.0× |
| SCYX SCYNEXIS, Inc. compare | −7.0× |
| RMTI Rockwell Medical, Inc. compare | −7.4× |
| IXHL Incannex Healthcare Inc. compare | −13.2× |
| TXMD TherapeuticsMD, Inc. | −34.4× |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | — |
| BGXXQ Bright Green Corporation compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets